Drug Trial Radar · NCT04956289
Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)
Last checked: Nov 20, 2026Latest source record: Aug 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jul 1, 2021
Primary completion
Jun 20, 2023
Study completion Jul 13, 2023
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Jul 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD patients over the age of 8 years.
Conditions
- Duchenne Muscular Dystrophy
Interventions
ViltolarsenDrug
Received during weekly intravenous infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse EventsTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Treatment Emergent Adverse Events by Maximum SeverityTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Treatment Emergent Adverse Events by Highest Intervention Level Regarding Investigational ProductTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Treatment Emergent Adverse Events by Worst OutcomeTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Investigational Product-related Treatment Emergent Adverse EventsTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Investigational Product-related Treatment Emergent Adverse Events by Maximum SeverityTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Investigational Product-related Treatment Emergent Adverse Events by Highest Intervention Level Regarding Investigational ProductTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Investigational Product-related Treatment Emergent Adverse Events by Worst OutcomeTime frame: baseline to up to 48 weeks of treatment
- Number of Participants With Adverse Event of Special InterestTime frame: baseline to up to 48 weeks of treatment
Locations
8 sites in 6 countries. Site status is shown where the registry gives one.
Children's Hospital of Richmond at VCU
Richmond, Virginia
The Third Medical Center of PLA General Hospital
Beijing, China
Hunan Children's Hospital
Changsha, China
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Roma, Italy
Russian National Research Medical University
Moscow, Russia
Saint Petersburg State Paediatric Medical University
Saint Petersburg, Russia
Hospital Sant Joan de Deu
Barcelona, Spain
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.